Genitourinary Cancers Symposium 2014

Sipuleucel-T Treatment Effects Persist Even in Radiation-Treated Patients

SAN FRANCISCO—Real-world data demonstrates that prior radiation therapy may no longer be a barrier for successful immunotherapy with sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC), according to research presented at the 2014 Genitourinary Cancers Symposium. Sipuleucel-T—an autologuous cellular immunotherapy indicated for patients with asymptomatic or minimally symptomatic mCRPC)—was approved by the US Food and Drug Administration based largely ... Read More »

Whole Pelvic Radiotherapy Superior in High-Risk Patients

SAN FRANCISCO—In prostate cancer patients with postoperative high-risk features for biochemical failure following radical prostatectomy, whole pelvic radiotherapy may improve biochemical outcome, according to results of a study completed recently by Jae-Sung Kim, PhD, and colleagues.  The researchers presented results of their study during a poster session at the 2014 Genitourinary Cancers Symposium. The poster was titled Whole Pelvic Irradiation ... Read More »

Older Age, Prolonged ADT Tied to Increased Risk of Diabetes and Cardiovascular Disease

SAN FRANCISCO—Although there was no observed increased risk in men with non-metastatic prostate cancer, age and length of androgen deprivation therapy (ADT) administration demonstrated a trend, indicating that further understanding of the mechanisms for this connection is needed.  ADT has been associated with an increased risk for developing diabetes and cardiovascular disease (CVD), but, as Alicia Katherine Morgans, MD, assistant ... Read More »

Trends in Use of Expectant Management of Low-Risk Prostate Cancer

SAN FRANCISCO—In older patients and in patients with multiple comorbidities, low-risk prostate cancer is increasingly being managed with expectant management (EM), including active surveillance and watchful waiting. One factor driving this increase in use of EM is the desire to minimize overtreatment of prostate cancer. Matthew J. Maurice, MD, and colleagues recently conducted a study to evaluate current trends in ... Read More »

Survey Reveals Referral Patterns of PCPs for Prostate Cancer Patients

SAN FRANCISCO—The role of the primary care physician (PCP) is an important facet of a multidisciplinary approach for the management of patients with prostate cancer, according to the results of a web-based survey of practicing PCPs in and around Boston, Massachusetts. Rajitha Sunkara, MD, and colleagues conducted the survey and reported results during a poster session at the 2014 Genitourinary ... Read More »

Height-Based Versus Weight-Based Dosing Regimen for Radium 223

SAN FRANCISCO—Researchers make a strong case for height-base dosing regimen when the intervention is designed only to treat the skeleton—as is the case with the radiopharmaceutical, radium 223.  Thomas Andrew Longo, MD, from the University of Nebraska Medical Center in Omaha, presented the results at the 2014 Genitourinary Cancers Symposium, and colleagues conducted a study looking at the safety profile ... Read More »

Sipuleucel-T Treatment Results in Humoral Spread Associated with Improved Overall Survival

SAN FRANCISCO—Overall survival (OS) was improved in patients with advanced prostate cancer following treatment with Provenge® (sipuleucel-T), according to results of the IMPACT, the pivotal trial of sipuleucel-T. Charles Drake, MD, and colleagues recently utilized data from the IMPACT trial to determine whether sipuleucel-T also elicits humoral antigen spread that may be associated with clinical benefit. They presented results of ... Read More »

One in Five Cancer Trials End Early due to Incomplete Enrollment

SAN FRANCISCO—The clinical trials enterprise is fraught with complications and obstacles to achieving results, particularly in the genitourinary oncology literature. Prostate cancer trials, however, seemed to largely escape the problems of early termination compared to all oncology trials. As part of a research effort to better understand the scope of the problem, Matthew D. Galsky, MD, and colleagues examined the ... Read More »

Obese Patients with Localized Prostate Cancer at Increased Risk of Biochemical Failure and Mortality

SAN FRANCISCO—Among patients with localized prostate cancer (CaP) receiving intensity-modulated radiation therapy (IMRT), those with higher levels of obesity may be at increased risk of biochemical failure (BF) and prostate cancer mortality. That was among the findings of a study conducted by Lora S. Wang, MD, and colleagues. Study results were reported during a poster session at the 2014 Genitourinary ... Read More »

Encouraging Results about Overall Response Rates in Patients Treated with ODM-201

SAN FRANCISCO—In one of several trials evaluating the safety and efficacy of the newer-generation androgen-blocker, ODM-201, at this year’s Genitourinary Cancers Symposium, the vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) were shown to reach stable disease at 12 weeks when treated with the novel agent. ODM-201 is a novel androgen-receptor inhibitor by blocking nuclear translocation; The ARADES ... Read More »